Insmed Inc (INSM)vsNektar Therapeutics (NKTR)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NKTR
Nektar Therapeutics
$72.08
-1.21%
HEALTHCARE · Cap: $2.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 998% more annual revenue ($606.42M vs $55.23M). INSM leads profitability with a -2.1% profit margin vs -297.1%. NKTR appears more attractively valued with a PEG of 0.31. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NKTR
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Growing faster than its price suggests
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 16.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -217.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NKTR
The strongest argument for NKTR centers on PEG Ratio. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NKTR
The primary concerns for NKTR are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
NKTR carries more volatility with a beta of 1.23 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NKTR generates stronger free cash flow (-65M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Nektar Therapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?